Key facts
- OxTium Technology’s last known valuation is $21.1M (Jan 2024).
- It has raised $3.9M; the latest was Early Stage VC in Nov 2025.
- Notable investors include HSG (Hong Kong), Shenzhen Nanshan Strategic Emerging Industry Investment, Shenzhen CDF Capital, Jiangxi Financial Holding Group, Shenzhen Lihe Science and Technology Innovation — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for OxTium Technology
- ·The full record, as it builds
Funding rounds
No funding rounds for OxTium Technology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About OxTium Technology
Developer of AI-driven bioscience platforms aims to advance computational intelligence in life science research and industrial applications. The company's offerings feature the AI research suite for cloud-native scientific exploration, the multi-omics large model framework for cross-modal biological interpretation, and an intelligent research ecosystem integrating pre-trained foundation models, enabling breakthroughs in precision diagnostics, industrial biomanufacturing, genomic breeding, and environmental bioengineering.
- Sector
- Healthcare
- HQ
- Shenzhen, China
- Founded
- 2022
- Website
- oxtium.com/
- Ownership
- Privately Held (backing)
OxTium Technology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in OxTium Technology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on OxTium Technology in its N-PORT filings yet. We sweep new filings monthly.